Cell therapy for diabetic neuropathy using adult stem or progenitor cells.
Cell therapy for diabetic neuropathy using adult stem or progenitor cells.
复制标题
DOI：
10.4093/dmj.2013.37.2.91
复制
发表时间：
2013-04
影响因子：
5.9
通讯作者：
Yoon YS
中科院分区：
文献类型：
--
作者：
Han JW;Sin MY;Yoon YS
糖尿病神经病变（DN）是糖尿病最常见和致残的并发症，可能导致足部溃疡和截肢。尽管人们普遍认识到 DN，但唯一有效的治疗方法是血糖控制和疼痛管理。越来越多的证据表明，DN 的特点是周围神经血管减少以及神经营养因子和血管生成因子缺乏。此前的研究曾尝试以蛋白质或基因的形式引入神经营养或血管生成因子进行治疗，但效果并不显着。最近的研究表明，骨髓（BM）来源的干细胞或祖细胞对心血管疾病的修复具有良好的作用。由于这些骨髓来源的干细胞或祖细胞含有各种血管生成和神经营养因子，因此这些细胞已被尝试用于治疗实验性 DN，并被证明可有效逆转实验性 DN 的各种表现。这些证据表明，影响血管和神经成分的细胞疗法可以代表治疗临床 DN 的一种新的治疗选择。
Diabetic neuropathy (DN) is the most common and disabling complication of diabetes that may lead to foot ulcers and limb amputations. Despite widespread awareness of DN, the only effective treatments are glucose control and pain management. A growing body of evidence suggests that DN is characterized by reduction of vascularity in peripheral nerves and deficiency in neurotrophic and angiogenic factors. Previous studies have tried to introduce neurotrophic or angiogenic factors in the form of protein or gene for therapy, but the effect was not significant. Recent studies have shown that bone marrow (BM)-derived stem or progenitor cells have favorable effects on the repair of cardiovascular diseases. Since these BM-derived stem or progenitor cells contain various angiogenic and neurotrophic factors, these cells have been attempted for treating experimental DN, and turned out to be effective for reversing various manifestations of experimental DN. These evidences suggest that cell therapy, affecting both vascular and neural components, can represent a novel therapeutic option for treatment of clinical DN.